8-K: NextPlat Reports $54M Revenue, Cuts Costs in 2025 Turnaround

NextPlat Corp announced its full-year 2025 financial results, reporting $54.3 million in revenue and a reduced net loss, driven by significant cost-cutting and strategic refocusing efforts.

Summary

• Consolidated revenue for the full year ended December 31, 2025, was approximately $54.3 million, an 18% decrease from $66.1 million in the prior year.
• Net loss attributable to common stockholders for 2025 was approximately $11.7 million, or ($0.44) per diluted share, an improvement from a net loss of $13.4 million, or ($0.65) per diluted share, in 2024.
• Total operating expenses decreased by approximately $20.1 million, or 50%, to $19.9 million in 2025, largely due to a 20% decrease in salaries and wages and a 49% decrease in professional fees.
• The company ended 2025 with approximately $13.7 million in cash, no meaningful unsecured debt, and approximately $15.0 million in working capital.
• Healthcare Operations revenue decreased by $12.6 million to $39.7 million, primarily due to a decrease in prescriptions filled, partially offset by increased reimbursement rates.
• e-Commerce revenues increased by $0.8 million to $14.6 million, driven by higher airtime and hardware sales and favorable foreign currency impact.
• Overall gross margin declined to approximately 20% in 2025 from 26% in 2024, with both healthcare and e-commerce segments experiencing decreases.
• The company successfully cut over $2 million in annualized costs, including reducing staff headcount by more than 25% and eliminating unused office space.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report. While top-line revenue and gross margins declined, the significant reduction in operating expenses and net loss, coupled with a clear strategic shift and optimistic 2026 outlook, indicates progress in the company's turnaround efforts.

Positives

• Net loss attributable to common stockholders improved to $11.7 million in 2025 from $13.4 million in 2024, reflecting effective cost management.
• Total operating expenses significantly decreased by 50% ($20.1 million) to $19.9 million, demonstrating successful cost-cutting and streamlining efforts.
• The company ended 2025 with a strong financial foundation, including $13.7 million in cash, no meaningful unsecured debt, and $15.0 million in working capital.
• e-Commerce revenues increased by $0.8 million to $14.6 million, driven by strong global demand for satellite-based connectivity and IoT products, setting new annual sales records for devices and trackers.
• Successful reengagement with 340B covered entities in Q4 2025 led to new, higher-margin medication fulfillment services exceeding 6,000+ prescriptions per month.
• Expansion of the senior leadership team with key appointments, including a new Chairman, CEO, CFO, and VP of Healthcare Operations.

Negatives

• Consolidated revenue for 2025 decreased by 18% to $54.3 million from $66.1 million in the prior year.
• Overall gross margin declined to approximately 20% in 2025 from 26% in 2024.
• Healthcare Operations revenue decreased by $12.6 million to $39.7 million, primarily due to a decrease in the number of total prescriptions filled (374,000 in 2025 vs. 473,000 in 2024) and a decrease in 340B contract revenue.
• e-Commerce Operations gross margin decreased slightly due to new airtime costs and temporary rate reductions for some customers affected by network service interruptions.

Risks

• The company's ability to launch additional e-commerce capabilities for consumer and healthcare products and its ability to grow and expand as intended.
• Known and unknown risks, uncertainties, and other factors that could cause the company to not achieve some or all of its goals or its previously reported actual results, performance (finance or operating).
• Temporary rate reductions for some e-commerce customers affected by ongoing network service interruptions impacting gross margins.

Future Outlook

NextPlat Corp anticipates being on a growth and profitability pathway in 2026, supported by a strong financial foundation and investments in business development, organizational process improvements, and enhanced customer service in healthcare operations. The company expects to significantly grow its business in the first half of 2026, with improved performance and profitability. Management also expects further meaningful reductions in operating expenses throughout 2026 and continued growth in higher-margin pharmacy contract services like 340B.

Management Comments

• David Phipps, CEO and President: "The closing of 2025 marks the start of an exciting new period for our company as we successfully execute on our turnaround and cost-cutting plans, efforts that began to drive fundamental improvements across operational and financial metrics in the fourth quarter, putting NextPlat on a growth and profitability pathway in 2026."
• David Phipps, CEO and President: "Looking into the first half of 2026, supported by a strong financial foundation and investments into business development, organizational process improvements, and enhanced customer service in our healthcare operations, we are now positioned to significantly grow the business. We believe the improved performance and profitability that we forecast for 2026 will finally deliver the value proposition that we’ve promised our shareholders for quite some time."

Industry Context

StockSavvy.ai notes that NextPlat's strategic shift towards higher-margin healthcare services, such as 340B contract revenue and medication fulfillment, aligns with a broader industry trend where healthcare providers seek to optimize revenue streams and operational efficiency. The continued growth in satellite-based connectivity and IoT products in its e-commerce segment also reflects increasing global demand for robust communication solutions, particularly in underserved or remote areas.

Management Changes

Legal Proceedings

• Loss on settlement of litigation of $250,000 for the year ended December 31, 2025.
• Contingent loss on settlement of litigation of $1,750,000 for the year ended December 31, 2025.

Related Party Transactions

• Due to related party balance of $82,000 as of December 31, 2025, compared to $48,000 as of December 31, 2024.

Stakeholder Impact

• Shareholders are promised improved performance and profitability in 2026, with the current results reflecting the initial phase of a turnaround.
• Employees experienced a reduction in staff headcount by more than 25% and a 20% decrease in salaries and wages as part of cost-cutting measures.
• Customers in healthcare operations are expected to benefit from enhanced customer service and a shift towards higher-margin services.
• Some e-commerce customers faced temporary rate reductions due to ongoing network service interruptions.

Next Steps

• Host a conference call on March 31, 2026, to discuss the results and recent developments.
• File the Annual Report on Form 10-K for the year ended December 31, 2025, with the SEC on March 31, 2026.
• Continue on a growth and profitability pathway in 2026.
• Significantly grow the business in the first half of 2026.
• Achieve further meaningful reductions in operating expenses throughout 2026.
• Continue growth in 340B contract revenue into the first half of 2026 with new covered entity contracts and increased prescription volumes.
• Evaluate several growth opportunities, including acquisitions and joint-ventures, to expand mail order medication fulfillment offerings nationwide and potentially launch direct-to-consumer online websites.

Key Dates

Recommendation

NextPlat's 2025 results present a mixed picture: significant revenue and gross margin declines are offset by substantial cost reductions and an improved net loss. The company is clearly in a transitional 'turnaround' phase, with management expressing strong optimism for growth and profitability in 2026 based on strategic shifts. A seasoned investor would likely 'hold' to observe if the forecasted 2026 improvements materialize and if the strategic pivot to higher-margin healthcare services can sustainably reverse top-line declines.

Keywords

NextPlat, NXPL, Financial Results, Earnings, Healthcare, e-Commerce, Cost Cutting, Turnaround, Revenue, Net Loss, Operating Expenses, 340B, Satellite Connectivity, IoT, SEC Filing, 8-K